Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 PK and safety study of BAX 826 versus ADVATE in severe hemophilia A
NL-OMON43447Phase 1Active, not recruiting
- Sponsor
- Baxter International Inc.
- Start
- Aug 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of BAX 826 in hemophilia A (3 cohorts), sponsored by Baxter International Inc. Primary endpoints: Adverse events, Safety and tolerability and 1 more. Started Aug 2016; status: active, not recruiting.
02
Drugs
BAX 826
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON43447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43447.